Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This first-in-human open-label, dose escalation study is designed to evaluate the safety,
tolerability, and PK of MRX-2843 in subjects with relapsed/refractory advanced and/or
metastatic solid tumors.